Phase I Study in Advanced Solid Tumors

Phase 1

• Conditions: Solid Tumors
• Interventions: Drug: indibulin

• Registration Number: NCT00591292
• Lead Sponsor: Alaunos Therapeutics

Brief Summary

Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2008-01-11
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-18
• Last Update Posted: 2012-07-19
• Primary Completion: 2013-06
• Study Completion: 2013-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	indibulin	-

Primary Outcome Measures

Name	Time	Method
toxicities	6 months

Secondary Outcome Measures

Name	Time	Method
pharmacokinetics	6 months